Moderna’s New mRNA Flu ‘Vaccine’ Wins FDA Approval
Originally published via Armageddon Prose:
In what is difficult to frame, try as apologists might, as anything other than a fresh betrayal of the MAHA coalition for the benefit of the pharmaceutical industry at the expense of (actual) public health, the FDA has just approved a Moderna mRNA influenza “vaccine” (mRNA shots being more accurately described as gene therapy than conventional vaccines).
Via Reuters:
“The U.S. Food and Drug Administration has approved Moderna’s (MRNA.O) flu vaccine for people aged 50 and older, the company said on Wednesday, marking the first approval of a messenger RNA-based vaccine for seasonal flu.
The shot, mFlusiva, was given a traditional approval for adults aged 50 to 64, and an accelerated approval for those 65 years and older…
Moderna has agreed to run an additional study and submit more data in adults 65 and older to confirm the vaccine’s benefit in that age group…
The approval was based on data from a late-stage trial involving more than 40,000 adults aged 50 and older, which showed the shot was 26.6% more effective than a licensed standard-dose flu vaccine.
The company also submitted separate late-stage data showing the vaccine generated stronger antibody responses than Sanofi’s high-dose flu vaccine in adults 65 and older.
MFlusiva would compete with flu vaccines from Sanofi (SASY.PA),, GSK (GSK.L), CSL Seqirus (CSL.AX),, and AstraZeneca (AZN.L)…
Jefferies analysts had forecast $750 million in U.S. sales of Moderna’s flu shot and combination COVID-flu vaccine by 2030.”
Related: Making a Killing: Americans Shelling Out up to $190 for COVID Boosters
-----------------------------------------
[If you appreciate Armageddon Prose, please consider a $5/month or $50/year Substack subscription or a one-time digital “coffee” donation. For alternative means of patronage, email benbartee@protonmail.com.]
------------------------------------------
The mechanism of action for Moderna’s new mRNA flu shot is identical to company’s COVID product, save that the spike protein produced by the mRNA in the former has been swapped for the influenza protein hemagglutinin (HA) protein in the latter.
In other words, the same risk of synthetic foreign proteins floating around the body and getting lodged in tissues, thereby potentially provoking crippling autoimmune responses, remains.
Related: Moderna Withheld Data From FDA Regulators to Get Bivalent Booster Approved
What’s more important than the inevitable death and suffering, though, is obviously that Moderna forecasts hundreds of millions of dollars in windfall profits over the next several years for the people who really matter: the shareholders.
You want to make an omelet, you gotta break some eggs (in women’s ovaries).
And all decent people support that trade-off.
We’re not communists, after all.
From Moderna’s press release, via Newswire:
“”The FDA approval of mFLUSIVA, our fourth approved product in the United States and the first mRNA-based flu vaccine, demonstrates the continued strength and versatility of our mRNA platform,” said Stéphane Bancel, Chief Executive Officer of Moderna. “Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America’s seniors. This approval also reflects the ongoing potential of our mRNA platform to help address important public health challenges through continued scientific innovation. We are grateful to the clinical trial participants, investigators, regulators and Moderna teams whose contributions made this milestone possible.”…
Moderna expects to have mFLUSIVA available for eligible populations in the U.S. for the 2026-2027 respiratory virus season, alongside Spikevax® (COVID-19 Vaccine, mRNA), mRESVIA® (Respiratory Syncytial Virus Vaccine) and mNEXSPIKE® (COVID-19 Vaccine, mRNA).”
Benjamin Bartee, author of Broken English Teacher: Notes From Exile (now available in paperback), is an independent Bangkok-based American journalist with opposable thumbs.
Follow AP on X.
Subscribe (for free) to Armageddon Prose and its dystopian sister, Armageddon Safari.
Support AP’s independent journalism with a one-off, hassle-free “digital coffee” tip or Patreon.
Bitcoin public address: bc1qvq4hgnx3eu09e0m2kk5uanxnm8ljfmpefwhawv